Roth Capital began coverage on shares of CryoPort (NASDAQ:CYRX) in a report published on Thursday, November 30th, Marketbeat reports. The brokerage issued a buy rating and a $12.50 price target on the consumer goods maker’s stock.
Several other brokerages have also commented on CYRX. Cowen boosted their price target on CryoPort from $5.50 to $7.50 and gave the company an outperform rating in a research note on Wednesday, August 9th. Janney Montgomery Scott lifted their price objective on CryoPort from $10.00 to $12.00 and gave the company a buy rating in a research report on Tuesday, October 3rd. Finally, Needham & Company LLC boosted their target price on CryoPort from $8.50 to $10.00 and gave the stock a buy rating in a research report on Wednesday, August 30th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $33.50.
Shares of CryoPort (NASDAQ CYRX) traded up $0.26 during trading hours on Thursday, hitting $8.59. CryoPort has a 52 week low of $1.96 and a 52 week high of $10.40.
Hedge funds have recently bought and sold shares of the company. Northern Trust Corp boosted its position in CryoPort by 105.0% during the second quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock valued at $109,000 after purchasing an additional 11,358 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CryoPort in the third quarter valued at approximately $118,000. Wolverine Trading LLC bought a new stake in CryoPort in the third quarter valued at approximately $230,000. Granite Investment Partners LLC bought a new position in shares of CryoPort during the third quarter worth approximately $535,000. Finally, EAM Investors LLC bought a new position in shares of CryoPort during the second quarter worth approximately $552,000. 18.17% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this piece of content on another website, it was copied illegally and reposted in violation of US and international trademark and copyright legislation. The original version of this piece of content can be read at https://www.truebluetribune.com/2017/12/11/cryoport-cyrx-receives-new-coverage-from-analysts-at-roth-capital.html.
Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.
Receive News & Ratings for CryoPort Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort Inc. and related companies with MarketBeat.com's FREE daily email newsletter.